Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central
nervous system (CNS), which gives rise to focal lesions in the gray and white matter and to …

In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …

There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Although the core concept of remyelination—based on the activation, migration, proliferation
and differentiation of CNS progenitors—has not changed over the past 20 years, our …

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that
causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …

Mitochondria are essential organelles within the cell where most ATP is produced through
oxidative phosphorylation (OXPHOS). A subset of the genes needed for this process are …

A better understanding of the pathological mechanisms that drive neurodegeneration in
individuals with multiple sclerosis is needed to develop therapies that will effectively treat …

Multiple sclerosis (MS) is the most frequent chronic inflammatory disease of the CNS, and
imposes major burdens on young lives. Great progress has been made in understanding …

Major progress has been made during the past three decades in understanding the
inflammatory process and pathogenetic mechanisms in multiple sclerosis (MS) …

In recent years, several studies have examined the potential associations between
mitochondrial dysfunction and neurodegenerative diseases such as multiple sclerosis (MS) …